Streetbeat News

Products Services

SNPX

Synaptogenix has received FDA authorization for its Investigational New Drug (IND) application to conduct a trial of Bryostatin-1 in treating Multiple Sclerosis.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:13 pm

ATLC

SYF

Synchrony (NYSE:SYF) and Atlanticus Holdings Corporation (NASDAQ:ATLC) have announced an enhanced multi-year partnership aimed at providing a preferred second look financing solution. This initiative is expected to drive business growth for merchants and partners by offering more customers access to credit.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:13 pm

KDLY

KindlyMD, Inc. (NASDAQ: KDLY) has successfully registered on SAM.gov and submitted its first grant application for the USDA Rural Utilities Service Distance Learning and Telemedicine Grant Program. This registration opens up numerous federal funding opportunities for the company.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:11 pm

UGRO

urban-gro, Inc. (NASDAQ:UGRO) has signed new contracts worth approximately $12 million in the cannabis sector. The contracts include engineering, architecture, design services, equipment procurement, and construction management. The majority of the revenue is expected to be recognized by the end of Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:10 pm

SHOT

Safety Shot has entered into a strategic partnership with Atlantic Beverage Distributors to expand its distribution into Massachusetts and Rhode Island. This marks a significant step in the company's expansion plan in the Northeast.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:10 pm

TRUG

TruGolf Holdings, Inc. (NASDAQ:TRUG) has signed an exclusive multi-year licensing deal with Golf Blueprint. This partnership will integrate Golf Blueprint's patent-pending technology into TruGolf's E6 APEX software, providing users with structured lesson plans to optimize practice and improve performance.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:08 pm

NRBO

NeuroBo Pharmaceuticals has dosed the first patient in the MAD Part 2 of its Phase 1 trial for DA-1726, an obesity treatment. Top-line data for Part 1 is expected in Q3 2024, and for Part 2 in Q1 2025. A planned Part 3 will assess weight loss at 24 weeks. The company has secured $70M in financing to fund ongoing clinical development.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:08 pm

AMZN

CHGG

Chegg has selected Amazon Web Services (AWS) as its preferred cloud provider to enhance its AI-powered learning solutions. This five-year agreement aims to leverage AWS's advanced AI capabilities to improve personalized learning experiences for students globally.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:07 pm

AAPL

Apple has expanded its Self Service Repair program to 32 European countries, allowing customers to access diagnostics and repair tools for their devices.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:05 pm

NXL

Nexalin Technology announced positive clinical study results for its DIFS® technology combined with escitalopram in treating major depressive disorder. The study showed significant improvement in two-thirds of patients receiving the combination therapy compared to one-third receiving medication alone.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:03 pm